189 related articles for article (PubMed ID: 24619883)
1. PPARγ activation attenuates glucose intolerance induced by mTOR inhibition with rapamycin in rats.
Festuccia WT; Blanchard PG; Belchior T; Chimin P; Paschoal VA; Magdalon J; Hirabara SM; Simões D; St-Pierre P; Carpinelli A; Marette A; Deshaies Y
Am J Physiol Endocrinol Metab; 2014 May; 306(9):E1046-54. PubMed ID: 24619883
[TBL] [Abstract][Full Text] [Related]
2. Major involvement of mTOR in the PPARγ-induced stimulation of adipose tissue lipid uptake and fat accretion.
Blanchard PG; Festuccia WT; Houde VP; St-Pierre P; Brûlé S; Turcotte V; Côté M; Bellmann K; Marette A; Deshaies Y
J Lipid Res; 2012 Jun; 53(6):1117-25. PubMed ID: 22467681
[TBL] [Abstract][Full Text] [Related]
3. Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue.
Houde VP; Brûlé S; Festuccia WT; Blanchard PG; Bellmann K; Deshaies Y; Marette A
Diabetes; 2010 Jun; 59(6):1338-48. PubMed ID: 20299475
[TBL] [Abstract][Full Text] [Related]
4. Hypoglycemic action of thiazolidinediones/peroxisome proliferator-activated receptor gamma by inhibition of the c-Jun NH2-terminal kinase pathway.
Díaz-Delfín J; Morales M; Caelles C
Diabetes; 2007 Jul; 56(7):1865-71. PubMed ID: 17416798
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor γ decouples fatty acid uptake from lipid inhibition of insulin signaling in skeletal muscle.
Hu S; Yao J; Howe AA; Menke BM; Sivitz WI; Spector AA; Norris AW
Mol Endocrinol; 2012 Jun; 26(6):977-88. PubMed ID: 22474127
[TBL] [Abstract][Full Text] [Related]
6. The PPARgamma agonist rosiglitazone enhances rat brown adipose tissue lipogenesis from glucose without altering glucose uptake.
Festuccia WT; Blanchard PG; Turcotte V; Laplante M; Sariahmetoglu M; Brindley DN; Richard D; Deshaies Y
Am J Physiol Regul Integr Comp Physiol; 2009 May; 296(5):R1327-35. PubMed ID: 19211718
[TBL] [Abstract][Full Text] [Related]
7. Rosiglitazone increases the expression of peroxisome proliferator-activated receptor-gamma target genes in adipose tissue, liver, and skeletal muscle in the sheep fetus in late gestation.
Muhlhausler BS; Morrison JL; McMillen IC
Endocrinology; 2009 Sep; 150(9):4287-94. PubMed ID: 19520784
[TBL] [Abstract][Full Text] [Related]
8. Metabolic action of peroxisome proliferator-activated receptor gamma agonism in rats with exogenous hypercorticosteronemia.
Berthiaume M; Laplante M; Tchernof A; Deshaies Y
Int J Obes (Lond); 2007 Nov; 31(11):1660-70. PubMed ID: 17579631
[TBL] [Abstract][Full Text] [Related]
9. mTOR partly mediates insulin resistance by phosphorylation of insulin receptor substrate-1 on serine(307) residues after burn.
Xin-Long C; Zhao-Fan X; Dao-Feng B; Wei D
Burns; 2011 Feb; 37(1):86-93. PubMed ID: 20594757
[TBL] [Abstract][Full Text] [Related]
10. Rosiglitazone, a PPARγ agonist, ameliorates palmitate-induced insulin resistance and apoptosis in skeletal muscle cells.
Meshkani R; Sadeghi A; Taheripak G; Zarghooni M; Gerayesh-Nejad S; Bakhtiyari S
Cell Biochem Funct; 2014 Dec; 32(8):683-91. PubMed ID: 25431031
[TBL] [Abstract][Full Text] [Related]
11. Leucine supplementation in rats induced a delay in muscle IR/PI3K signaling pathway associated with overall impaired glucose tolerance.
Balage M; Dupont J; Mothe-Satney I; Tesseraud S; Mosoni L; Dardevet D
J Nutr Biochem; 2011 Mar; 22(3):219-26. PubMed ID: 20558053
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome proliferator-activated receptor γ ligands retard cultured vascular smooth muscle cells calcification induced by high glucose.
Zhou YB; Zhang J; Peng DQ; Chang JR; Cai Y; Yu YR; Jia MZ; Wu W; Guan YF; Tang CS; Qi YF
Cell Biochem Biophys; 2013 Jul; 66(3):421-9. PubMed ID: 23274912
[TBL] [Abstract][Full Text] [Related]
13. Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats.
Deblon N; Bourgoin L; Veyrat-Durebex C; Peyrou M; Vinciguerra M; Caillon A; Maeder C; Fournier M; Montet X; Rohner-Jeanrenaud F; Foti M
Br J Pharmacol; 2012 Apr; 165(7):2325-40. PubMed ID: 22014210
[TBL] [Abstract][Full Text] [Related]
14. Mechanism by which a novel non-thiazolidinedione peroxisome proliferator-activated receptor gamma agonist, FK614, ameliorates insulin resistance in Zucker fatty rats.
Minoura H; Takeshita S; Kimura C; Hirosumi J; Takakura S; Kawamura I; Seki J; Manda T; Mutoh S
Diabetes Obes Metab; 2007 May; 9(3):369-78. PubMed ID: 17391165
[TBL] [Abstract][Full Text] [Related]
15. Exercise reverses high-fat diet-induced impairments on compartmentalization and activation of components of the insulin-signaling cascade in skeletal muscle.
Yaspelkis BB; Lessard SJ; Reeder DW; Limon JJ; Saito M; Rivas DA; Kvasha I; Hawley JA
Am J Physiol Endocrinol Metab; 2007 Oct; 293(4):E941-9. PubMed ID: 17623749
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of human insulin gene transcription by peroxisome proliferator-activated receptor gamma and thiazolidinedione oral antidiabetic drugs.
Schinner S; Krätzner R; Baun D; Dickel C; Blume R; Oetjen E
Br J Pharmacol; 2009 Jul; 157(5):736-45. PubMed ID: 19338578
[TBL] [Abstract][Full Text] [Related]
17. Tissue-specific effects of rosiglitazone and exercise in the treatment of lipid-induced insulin resistance.
Lessard SJ; Rivas DA; Chen ZP; Bonen A; Febbraio MA; Reeder DW; Kemp BE; Yaspelkis BB; Hawley JA
Diabetes; 2007 Jul; 56(7):1856-64. PubMed ID: 17440174
[TBL] [Abstract][Full Text] [Related]
18. S26948, a new specific peroxisome proliferator activated receptor gamma modulator improved in vivo hepatic insulin sensitivity in 48 h lipid infused rats.
Sohn KA; Cruciani-Guglielmacci C; Kassis N; Clément L; Ouali F; Caüzac M; Lebègue N; Berthelot P; Caignard DH; Pégorier JP; Renard P; Dacquet C; Ktorza A; Magnan C;
Eur J Pharmacol; 2009 Apr; 608(1-3):104-11. PubMed ID: 19250932
[TBL] [Abstract][Full Text] [Related]
19. Insulin-sensitizing effect of rosiglitazone (BRL-49653) by regulation of glucose transporters in muscle and fat of Zucker rats.
Kramer D; Shapiro R; Adler A; Bush E; Rondinone CM
Metabolism; 2001 Nov; 50(11):1294-300. PubMed ID: 11699047
[TBL] [Abstract][Full Text] [Related]
20. Depot-specific effects of the PPARgamma agonist rosiglitazone on adipose tissue glucose uptake and metabolism.
Festuccia WT; Blanchard PG; Turcotte V; Laplante M; Sariahmetoglu M; Brindley DN; Deshaies Y
J Lipid Res; 2009 Jun; 50(6):1185-94. PubMed ID: 19201733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
